1. Goldman Sachs Annual Global
Healthcare Conference
Geno Germano
President – U.S. and General Manager,
Wyeth Pharmaceuticals
June 12, 2007

2. Forward-Looking Statement
The statements in this presentation that are not historical facts are forward-
looking statements based on current expectations of future events that
involve risks and uncertainties including, without limitation, risks
associated with the inherent uncertainty of pharmaceutical research,
product development, manufacturing, commercialization, economic
conditions including interest and currency exchange rate fluctuations, the
impact of competitive or generic products, product liability and other types
of lawsuits, the impact of legislative and regulatory compliance and
obtaining approvals, and patent, and other risks and uncertainties,
including those detailed from time to time in Wyeth’s periodic reports,
including quarterly reports on Form 10-Q and the annual report on Form 10-
K, filed with the Securities and Exchange Commission. Quarterly results, in
particular, can vary due to issues which include, but are not limited to,
changes in exchange rates, the timing of actions taken by the Company to
ensure long-term improvements to our manufacturing processes, the
timing of regulatory approval of new products and/or facilities and the
timing of promotional programs. Actual results may vary materially from
the forward-looking statements. The Company assumes no obligation to
publicly update any forward-looking statements, whether as a result of new
information, future events or otherwise.

3. Driving Wyeth’s Growth
Reliable Safety and Efficacy Profile
n
4 Over 470,000 Patients Treated Worldwide
4 Over One Million Patient Years Market Experience
~360,000 Incremental Biologic Patients in Top 6 EU Countries
n
~60,000 Incremental Biologic Patients in Japan
n
4 Japanese Post Marketing Surveillance Program Lifted 2Q07
Significant Growth Opportunities Exist
n
4 Biologics Market Penetration:
- RA: U.S. = ~33%; EU = ~20%
- Psoriasis: U.S. = ~8%; EU = <1%
$3 Billion Enbrel Sales in 2010
(Outside North America)

4. Driving Wyeth’s Growth
®
Launched in 79 Countries; Additional 9 Launches by 2008
n
Current and Emerging Market Opportunities Birth Cohorts
Current National Immunization Programs ~ 10 Million
(16 Programs to Date)
Potential National Immunization Programs ~ 3 Million
(e.g. Austria, Denmark, Finland, Ireland, Japan)
Private to Potential National Immunization Programs ~ 8 Million
(e.g. Brazil, Czech Republic, Turkey)
Private Markets ~ 58 Million
(e.g. China, India, Pakistan, Russia)
$3 Billion Prevnar Sales in 2010
(Infant Vaccination)

5. Recent FDA Approvals
Lybrel ™ - Approved May 2007
n
4First Low Dose Combination Oral Contraceptive Offering Women the
Opportunity to Be Period-Free Over Time
4U.S. Launch Expected in July 2007
Torisel ™ - Approved May 2007
n
4Targeted First-in-Class mTOR Inhibitor for the Treatment of Advanced
Kidney Cancer
4Proven to Extend Overall Survival for People with Advanced Renal Cell
Carcinoma
4U.S. Launch Expected in July 2007

6. Future Wyeth Growth Drivers
New Pharmaceutical Products Pending FDA Approval
Expected FDA
Project Indication
Action
Pristiq™ Vasomotor Late July 2007
Bifeprunox Schizophrenia August 2007
Viviant™ Osteo Prevention Year End 2007
Pristiq™ Depression 1Q 2008
Methylnaltrexone Opioid Induced
January 2008
(Sub Q) Constipation

7. Pristiq™: A Single Product With Multiple Uses
in a Large Population
Vasomotor Symptoms
Depression
First Line Treatment of First FDA-Approved
n n
Major Depressive Disorder Non-Hormonal Treatment of
Associated With Menopause Moderate-to-Severe VMS
Excellent Results Achieved
n
Submitted Results From Study
n
With Low Dose Studies
of 100 mg and 150 mg Doses
4 Demonstrated Efficacy at 50 mg
With Three-day 50 mg Starting
Dose
Dose
4 Replicated Efficacy at 100 mg Dose
4 Markedly Reduced Incidence of
4 Reduction in Adverse Event Related
Nausea and Adverse Event Related
Discontinuation Rates
Discontinuations
4 Substantial Improvement in Nausea
Rates and Overall Tolerability 4 Confirmed Efficacy of the 100 mg
and 150 mg Doses
50 mg Dose is Optimal Dose
n
for Depression

8. Pristiq™ Market Possibilities
(U.S.)
12 Million 4 Million
23 Million +
+ Women Women >35 Million Women
Women
U.S. Prevalence1)
Vasomotor
Vasomotor Fibromyalgia
MDD Fibromyalgia
MDD
Symptoms
Symptoms
GAD
GAD
SAD
SAD
Panic
Panic
2006
~2 to 3 Million
Patients
1) 2006 Syndicated Depression Omnibus shows VMS and
depression overlap of ~3M women, 2005 Depression
Consumer; Landscape Study shows fibromyalgia and
depression overlap of ~1M women

9. Future Wyeth Growth Drivers
Near Term FDA Submissions
Project Indication Proposed Filing
ReFacto® AF Hemophilia Submitted 2Q07
Tygacil® CAP/HAP Mid 2007
Menopausal
Aprela™ Symptoms/ Late 2007
Osteoporosis
Methylnaltrexone Post Operative
Early 2008
(I.V.) Ileus

10. Aprela™: Optimal Targeted Response of
Tissue Selective Estrogens Complex (TSEC)
Product Profile
n
4Relieves Vasomotor Symptoms
4Prevents Osteoporosis
4Improves Vulvovaginal Atrophy (VVA)
4Excellent Amenorrhea
4Less Breast Tenderness
4Provides Endometrial Protection Without Progestin
NDA Filing: Late 2007
n
The Most Comprehensive Medicine
for Menopause

11. Aprela™ Market Possibilities
Premarin Family in 2001
~13 Million Women Worldwide
n
Global Revenue = $2 Billion
Less Than $1.00 Per Day
n
Premarin Family Today
~3 Million Women Worldwide
n
Global Revenue = $1 Billion
About $1.00 Per Day
n
Aprela’s Possibilities
Capture a % of Lost Patients
n
Global Revenueð$2 Billion +
Modern Day Pricing
n

12. Positioning Wyeth To Be A Stronger
Company
Build Breadth and Diversity Into Every Aspect of the
n
Company So Wyeth Will Never Be Dependent on One
Product or Any One Research Program
Continue to Improve Profitability by Enhancing Productivity
n
Achieve Solid Top Line Growth, Effectively Manage Costs,
n
and Grow the Bottom Line at a Meaningfully Faster Rate
Than the Growth in Revenues
Position Wyeth to Be a Stronger Company at the End of the
Decade Then We Are Today and Enter the Next Decade With
Great Momentum